Welcome to MicroDose

MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc. (see press release)

MicroDose Technologies Grants Global License to Merck & Co., Inc., for Use of the MicroDose Inhaler with Merck's Proprietary Products. (see press release)

MicroDose Technologies Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study. (see press release)

MicroDose Technologies Announces Multi-Product Respiratory Collaboration for its Next Generation Inhaler Device. MONMOUTH JUNCTION, N.J., June 28 (see press release)

Innovata and Microdose regain rights to inhaled insulin from Bristol-Myers Squibb. Innovata plc (LSE: IOV.L) today announced the restructuring of the agreement between QDose, its joint venture with MicroDose Technologies Inc. (MicroDose), and Bristol-Myers Squibb Company (NYSE: BMY) relating to fast acting inhaled insulin. Bristol-Myers Squibb has decided to reallocate resources dedicated to QDose to other pipeline priorities and has transferred to QDose all rights to the product. (see press release)

3M and MicroDose Technologies team up to bring advanced Electronic Dry Powder Inhaler technology to market. Collaboration will provide fully Integrated Drug Delivery Solutions for the Pharmaceutical and Biotechnology Industries. July, 2004 (see press release)

Bristol-Myers Squibb and QDose Announce Collaboration To Develop Inhaled Insulin For The Treatment of Diabetes. September, 2003 (see press release)

MicroDose and University of Pittsburgh receives Department of Defense grant to develop delivery system for nerve agent poisoning antidote. October, 2003 (see press release)

Microdose Reports Success In First Clinical Trial For Inhaled Insulin Using Novel Microdose Device; Needle-Free Alternative For Diabetes Treatment. December, 2001 (see press release)

Joint Venture With Microdose Technologies To Exploit Pulmonary Delivery Of Peptides And Proteins. November, 1999 (see press release)

Please visit our User Agreement. Your continued use of this site will automatically constitute your agreement to be bound by all the terms and conditions of the User Agreement.